NO20012555L - Fremgangsmåte for å fremme cervikale og vaginale sekresjoner - Google Patents

Fremgangsmåte for å fremme cervikale og vaginale sekresjoner

Info

Publication number
NO20012555L
NO20012555L NO20012555A NO20012555A NO20012555L NO 20012555 L NO20012555 L NO 20012555L NO 20012555 A NO20012555 A NO 20012555A NO 20012555 A NO20012555 A NO 20012555A NO 20012555 L NO20012555 L NO 20012555L
Authority
NO
Norway
Prior art keywords
triphosphate
vaginal secretions
treatment
receptor agonists
purinergic receptor
Prior art date
Application number
NO20012555A
Other languages
English (en)
Other versions
NO20012555D0 (no
Inventor
William Pendergast
Sammy R Shaver
David J Drutz
Janet L Rideout
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of NO20012555D0 publication Critical patent/NO20012555D0/no
Publication of NO20012555L publication Critical patent/NO20012555L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for å stimulere cervikale og vaginale sekresjoner i et pattedyr ved behandling med P2Y2 og/eller P2Y4 purinergiske reseptor- agonister. Behandling av vaginal tørrhet assosiert med menopause, kjemoterapi og forskjellige sykdomstilstander så vel som-behandlingen av vulvasmerte er omtalt. Passende purinergiske reseptoragonister inkluderer nukleotidtrifos- fater som uridin-5'-trifosfat, cytidin-5'-trifosfat og adenosin-5'-trifosfat, dinukleotidpolyfosfater som P1P4-di- (uridin-5')tetrafosfat og deres analoger. Disse purinergiske reseptoragonister er anvendbare til å stimulere cervikale og vaginale sekresjoner og behandle vaginal tørrhet i pattedyr.
NO20012555A 1998-11-25 2001-05-23 Fremgangsmåte for å fremme cervikale og vaginale sekresjoner NO20012555L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/199,912 US6462028B2 (en) 1997-07-25 1998-11-25 Method of promoting cervical and vaginal secretions
PCT/US1999/027634 WO2000030629A2 (en) 1998-11-25 1999-11-19 Method of promoting cervical and vaginal secretions

Publications (2)

Publication Number Publication Date
NO20012555D0 NO20012555D0 (no) 2001-05-23
NO20012555L true NO20012555L (no) 2001-07-24

Family

ID=22739534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012555A NO20012555L (no) 1998-11-25 2001-05-23 Fremgangsmåte for å fremme cervikale og vaginale sekresjoner

Country Status (12)

Country Link
US (2) US6462028B2 (no)
EP (1) EP1133304A2 (no)
JP (1) JP2003524609A (no)
KR (1) KR20010101066A (no)
CN (1) CN1348378A (no)
AU (1) AU764452B2 (no)
BR (1) BR9915636A (no)
CA (1) CA2352262A1 (no)
ID (1) ID29801A (no)
NO (1) NO20012555L (no)
WO (1) WO2000030629A2 (no)
ZA (1) ZA200104310B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7078391B2 (en) 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
AU747196B2 (en) 1997-07-25 2002-05-09 Merck Sharp & Dohme Corp. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7109181B2 (en) 2001-06-25 2006-09-19 Inspire Pharmaceuticals, Inc. Joint lubrication with P2Y purinergic receptor agonists
CN1612739A (zh) 2001-11-06 2005-05-04 印斯拜尔药品股份有限公司 治疗或预防炎性疾病的方法
EP1348466A3 (en) * 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US20030162769A1 (en) * 2002-02-26 2003-08-28 Easterling W. Jerry Composition and method for treating vulvodynia
US20050176782A1 (en) * 2002-02-26 2005-08-11 Easterling W. J. Medicament and method for treating vulodynia
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
GB0312845D0 (en) * 2003-06-04 2003-07-09 Paradigm Therapeutics Ltd Use of componds in medicine
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US8147399B2 (en) 2004-05-11 2012-04-03 Gloth David A Device and method for applying a biocompatible substance to a female stimulation device
US6949067B1 (en) * 2004-05-11 2005-09-27 Dann Jeffrey A Device and method for enhancing female sexual stimulation
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
DE102004054552A1 (de) 2004-11-11 2006-05-18 Hcb Happy Child Birth Holding Ag Neue Zusammensetzung zur Erleichterung der Humangeburt
US7368439B2 (en) 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
GB201209244D0 (en) * 2012-05-25 2012-07-04 Globalacorn Ltd Compositions
WO2014057096A1 (en) * 2012-10-12 2014-04-17 Inoflex Ab Composition for alleviating conditions associated with vaginal dryness
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
GB201320959D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639561A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US3639562A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
JPH05346549A (ja) 1992-04-17 1993-12-27 Canon Inc 走査光学装置
EP0566135A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
IT1277373B1 (it) * 1995-07-28 1997-11-10 Consiglio Nazionale Ricerche Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato
US6423694B1 (en) 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
ATE335492T1 (de) 1996-03-27 2006-09-15 Inspire Pharmaceuticals Inc Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US6319908B1 (en) * 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998034942A2 (en) 1997-02-06 1998-08-13 Inspire Pharmaceuticals, Inc. Dinucleotides and their use
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
AU747196B2 (en) * 1997-07-25 2002-05-09 Merck Sharp & Dohme Corp. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women

Also Published As

Publication number Publication date
US20080214490A1 (en) 2008-09-04
US6462028B2 (en) 2002-10-08
US20020013289A1 (en) 2002-01-31
EP1133304A2 (en) 2001-09-19
ZA200104310B (en) 2002-10-24
ID29801A (id) 2001-10-11
WO2000030629A3 (en) 2001-06-07
WO2000030629A2 (en) 2000-06-02
KR20010101066A (ko) 2001-11-14
NO20012555D0 (no) 2001-05-23
CA2352262A1 (en) 2000-06-02
JP2003524609A (ja) 2003-08-19
CN1348378A (zh) 2002-05-08
AU764452B2 (en) 2003-08-21
BR9915636A (pt) 2002-12-24
AU1741200A (en) 2000-06-13

Similar Documents

Publication Publication Date Title
NO20012555L (no) Fremgangsmåte for å fremme cervikale og vaginale sekresjoner
DK1012154T3 (da) Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf
NZ333983A (en) Method of treating sinusitis with uridine triphosphates and related compounds
US6140496A (en) Precursors for deoxyribonucleotides containing non-standard nucleosides
Huang et al. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis
ATE196912T1 (de) Propargylethoxyamino nucleotide
AR001045A1 (es) Procedimiento para purificar y aislar 2'-desoxi-2',2'-difluoronucleosidos enriquecidos en beta anomeros
Lazarowski et al. Enzymatic synthesis of UTPγS, a potent hydrolysis resistant agonist of P2U‐purinoceptors
BR0114837A (pt) nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
NZ543867A (en) Modified fluorinated nucleoside analogues
NO914859L (no) 3'-(2')-amino- eller tiolmodifiserte, fluorescensfarvestoffkoblede nukleosider, nukleotider og oligonukleotider, samt fremgangsmaate for fremstilling og anvendelse derav
BRPI0518984A2 (pt) anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal
JP2009167170A (ja) Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用
JP2005508297A5 (no)
ES2058908T3 (es) Procedimiento para la separacion y purificacion de sialil-transferasas.
AU1359992A (en) Adenosine kinase inhibitors
JP2005532254A5 (no)
Abe et al. Role of dephosphorylation in accumulation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity
Daifuku Stealth nucleosides: mode of action and potential use in the treatment of viral diseases
ATE186837T1 (de) Analoge des ajca-ribosids
Azuma et al. Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)
Nedeljkovic et al. Early temporal changes in ecto-nucleotidase activity after cortical stab injury in rat
Miura et al. The Antitumor Mechanism of 1‐(2‐Deoxy‐2‐fluoro‐4‐thio‐β‐D‐arabinofuranosyl)‐cytosine: Effects of Its Triphosphate on Mammalian DNA Polymerases
BRPI0816498A2 (pt) combinações potentes de zidovudina e drogas que selecionam para a mutuação k65r na polimerase do hiv
RU2183213C2 (ru) Модифицированные нуклеозид-5'-трифосфаты как антивирусные агенты

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application